BMS-214662

N/A

Report date: 2022/09/05 10:49:19
NME

Base Information

Drug NameBMS-214662
Drug Alias NameBMS-214662
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein farnesyltransferase inhibitors
TargetsProtein farnesyltransferase
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesAnemia, Refractory, with Excess of Blasts +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesAnemia, Refractory, with Excess of Blasts +[12] 

Other Information

ATC CodeN/A
Related LinksN/A